Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02873286 · ClinicalTrials.gov registry record · Phase 2
RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
A Phase 2 study, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 2
- Development phase
- 420
- Enrollment target
NCT02873286: Completed Phase 2 study, sponsored by Bavarian Nordic.
NCT02873286 is a Phase 2 study that has completed, run by Bavarian Nordic. The registered enrollment target is 420 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (216% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02873286, a Phase 2 study, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 420 participants
- Enrollment target
Study Summary
A total of 400 subjects will be recruited into five treatment subject groups à 80 subjects.Subject will receive two administrations 4 weeks apart which will consist of MVA-BN-RSV Dose 1, MVA-BN-RSV Dose 2 or Placebo (TBS). 86 subjects from 2 treatment groups (43 per treatment group) are supposed to receive one (booster) dose of MVA-BN-RSV vaccine approximately one year after their first vaccination. In this booster substudy, eligible subjects will receive the same dose they received during the main trial.
Primary Outcome
Geometric Mean Titers (GMTs) based on RSV-specific Plaque Reduction Neutralization Test (PRNT; against subtype A). Titers below the detection limit (DL) are included with a value of '10' (i.e. 1/2 DL)
Interventions
- OTHER Placebo
- BIOLOGICAL MVA-BN-RSV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2016-09 |
| Est. Completion | 2018-12 |
| Phase | Phase 2 |
What the finished NCT02873286 record still lists
NCT02873286 is an interventional study that assigns participants to a tested intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (216% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02873286 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02873286 about?
NCT02873286 is a clinical study titled "RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults". A total of 400 subjects will be recruited into five treatment subject groups à 80 subjects.Subject will receive two administrations 4 weeks apart which will consist of MVA-BN-RSV Dose 1, MVA-BN-RSV Dose 2 or Placebo (TBS). 86 subjects from 2 treatment groups (43 per treatment group) are supposed to...
What is the current status of trial NCT02873286?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 420 participants. The study started on 2016-09. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02873286?
The interventions under investigation include: Placebo (OTHER), MVA-BN-RSV (BIOLOGICAL).
Who is sponsoring clinical trial NCT02873286?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02873286's enrollment target sits among peer trials
420 91st of 2000 higher than 1,910 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia